GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2021 Earnings Conference Call March 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE, Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer John Sharkey - Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Year End 2021 Corporate Update Call. I am Chuck with Cho ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of 87-0455038 (IRS Employer Identification Number) 1900 Lake Park ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Jules Abraham - Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Newman - Chief Scientific Officer Mark Reynolds - Chief Financial Officer John Sharkey - Head, Business Development Don Diamond - Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 (Address of principal executive of ices) (Zip Code (State or other jurisdiction (IRS Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants Jules Abraham - CORE, Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Newman - Chief Scientific Officer Mark Reynolds - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Jeffrey Kraws - Crystal Research Operator Good day and welcome to the GeoVax Second Quarter 2021 Corporate Update Call. I am [Gran], with Chorus Call and will facilitate ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0455038 (State or other jurisdiction (IRS Employer Id ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Jules Abraham - Director of Public Relations, CORE IR David Dodd - Chairman & Chief Executive Officer Mark Newman - Chief Scientific Officer Mark Reynolds - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Kumar Raja - Brookline Capital Markets Jeffrey Kraws - Crystal Research Operator Good afternoon, and welcome everyone to the GeoVax First Quarter 2021 Conference Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39563 GEOVAX LABS, INC. Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2020 Earnings Conference Call March 24, 2021 8:00 AM ET Company Participants Scott Gordon - MD, CORE IR David Dodd - Chairman & CEO Mark Reynolds - CFO Mark Newman - Chief Scientific Officer Conference Call Participants Jason McCarthy - Maxim Group Operator Good morning and welcome everyone to the GeoVax Fourth Quarter Year-end 2020 Corporate Update Call. I am Jayson with Chorus Call and will facilitate today's call. With me are David Dodd, Chairman and CEO; Mark Reynolds, ...

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑ (Exact name of registra ...